Skip to main content
OpenTrials
Completed

NCT Number: NCT00546351

Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.

SP746 (NCT00546351) is a multi-center, open-label, follow-on trial. The purpose of this trial is to assess safety and tolerability of long-term exposure of lacosamide (previously referred to as SPM 927) in subjects with painful distal diabetic neuropathy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Painful Diabetic Neuropathy Diabetes Complications Diabetes Mellitus Diabetic Neuropathies Endocrine System Diseases Nervous System Diseases Neuromuscular Diseases Peripheral Nervous System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

180, Vienna, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who completed Study SP743 (NCT00238524) or SP874 (NCT00350103) and, in the investigator's opinion, might benefit from long-term administration of SP746 (NCT00546351). Exception: subjects who prematurely discontinued
  • SP743 (NCT00238524) or SP874 (NCT00350103) due to lack of efficacy or due to intolerability to trial medication (after Visit 5but prior to entering the Maintenance Phase) may be eligible to participate in SP746 (NCT00546351), after consultation with the medical monitor

Exclusion criteria

  • Subject has clinically relevant ECG abnormalities, or a QTc interval ≥500 ms, and/or a QTc interval increase of ≥60 ms from the mean pre-dose QTc value at Visit 2 of SP743 (NCT00238524) or SP874 (NCT00350103)
  • Subject has aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≥3 times the upper limit of the normal range (ULN) with total bilirubin ≥2 times ULN or transaminases (AST and/or ALT) ≥5 times ULN
  • Subject has a clinically relevant medical condition that, in the opinion of the investigator, jeopardizes or compromises the subject's ability to participate in this trial
  • Subject is a pregnant or nursing female, or is of childbearing potential and is not surgically sterile, 2 years postmenopausal, or does not practice 2 combined methods of contraception

Treatment and study plan

Lacosamide

Drug

50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years

Other names: Vimpat

Primary outcomes

  1. Number of Participants Experiencing the Occurrence of at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).

    Time frame: From entry Visit 1 through end of treatment (approximately 6.5 years)

    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

  2. Number of Participants Experiencing the Occurrence of at Least One Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).

    Time frame: From entry Visit 1 through end of treatment (approximately 6.5 years)

    A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:

    • Is fatal
    • Is life-threatening
    • Results in persistent or significant disability/incapacity
    • Requires inpatient hospitalization
    • Prolongs existing inpatient hospitalization
    • Is a congenital anomaly/birth defect
    • Is considered to be an important medical event. Such an event may not be immediately life threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes listed in the definitions above

Secondary outcomes

  1. Average Daily Pain Score Using an 11-point Likert Scale (0-10) at Baseline Visit.

    Time frame: Baseline

    On the Likert Scale, 0 = no pain and 10 = worst possible pain.

  2. Average Daily Pain Score Using an 11-point Likert Scale (0-10) at Last Visit.

    Time frame: Last Visit (approximately 2 years)

    On the Likert Scale, 0 = no pain and 10 = worst possible pain.

  3. Average Pain Score as Measured by a 100 mm Visual Analog Scale (VAS) at Baseline.

    Time frame: Baseline

    Visual Analog Scale (VAS) 0 mm = no pain and 100 mm = worst possible pain.

  4. Average Pain Score as Measured by a 100 mm Visual Analogue Scale (VAS) at Last Visit.

    Time frame: Last Visit (approximately 2 years)

    On VAS 0 mm = no pain and 100 mm = worst possible pain.

  5. Patient's Global Impression of Change (PGIC) at Last Visit.

    Time frame: Last Visit (approximately 2 years)

    The PGIC is a 7-point self-administered categorical rating scale in which the subject rated the change in pain since starting trial medication (from much worse [score of 1] to much better [score of 7]).

    Reported results are presented as Better (sum of mildly, moderately, or much better), No Change, or Worse (sum of mildly, moderately, or much worse).

  6. Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Intensity at Last Visit.

    Time frame: Baseline Visit; Last Visit (approximately 2 years)

    0 = no pain and 10 = most intense pain sensation imaginable.

  7. Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Sharpness at Last Visit.

    Time frame: Baseline Visit; Last Visit (approximately 2 years)

    0 = not sharp and 10 = most sharp sensation imaginable.

  8. Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Heat at Last Visit.

    Time frame: Baseline Visit; Last Visit (approximately 2 years)

    0 = not hot and 10 = the most hot sensation imaginable.

  9. Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Cold at Last Visit.

    Time frame: Baseline Visit; Last Visit (approximately 2 years)

    0 = not cold and 10 = the coldest sensation imaginable.

  10. Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Dullness at Last Visit.

    Time frame: Baseline Visit; Last Visit (approximately 2 years)

    0 = not dull and 10 = most dull sensation imaginable.

  11. Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Unpleasantness at Final Visit.

    Time frame: Baseline Visit; Last Visit (approximately 2 years)

    0 = not unpleasant and 10 = most unpleasant sensation imaginable.

  12. Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Surface Pain at Last Visit.

    Time frame: Baseline Visit; Last Visit (approximately 2 years)

    0 = no surface pain and 10 = most intense surface pain imaginable.

  13. Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Deep Pain at Last Visit.

    Time frame: Baseline Visit; Last Visit (approximately 2 years)

    0 = no deep pain and 10 = most intense deep pain imaginable.

  14. Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Itchiness at Final Visit.

    Time frame: Baseline Visit; Last Visit (approximately 2 years)

    0 = not itchy and 10 = most itchy sensation imaginable.

  15. Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Sensitivity at Last Visit.

    Time frame: Baseline Visit; Last Visit (approximately 2 years)

    0 = not sensitive and 10 = most sensitive sensation imaginable.

  16. Average Pain Interference With Sleep (11-point Likert Scale) at Baseline.

    Time frame: Baseline

    0 = no interference with sleep and 10 = worst possible interference with sleep.

  17. Average Pain Interference With Sleep (11-point Likert Scale) at Last Visit.

    Time frame: Last Visit

    0 = no interference with sleep and 10 = worst possible interference with sleep.

  18. Average Pain Interference With Activity (11-point Likert Scale) at Baseline.

    Time frame: Baseline

    0 = no interference with activity and 10 = worst possible interference with activity.

  19. Average Pain Interference With Activity (11-point Likert Scale) at Last Visit.

    Time frame: Last Visit

    0 = no interference with activity and 10 = worst possible interference with activity.

  20. Average Quality of Life Using the SF-36 Health Survey - Physical Component Summary (PCS) at Baseline.

    Time frame: Baseline

    The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.

  21. Average Quality of Life Using the SF-36 Health Survey - Physical Component Summary (PCS) at Last Visit.

    Time frame: Last Visit

    The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.

  22. Average Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS) at Baseline.

    Time frame: Baseline

    The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.

  23. Average Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS) at Last Visit.

    Time frame: Last Visit

    The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.

Sponsors and collaborators

Lead sponsor

UCB Pharma

Industry

Registry information

Official study title

A Multi-center, Open-label, follow-on Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy Including a Double-blind, Randomized Time Point Withdrawal Subtrial.

Important dates

Study start
2004
Primary completion
2011
Study completion
2011
First posted
Oct 18, 2007
Registry last updated
Sep 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.